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Molecular characterisation of two cell lines selected for resistance to the
folate-based thymidylate synthase inhibitor, ZD1694
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S_inminary Resistance to anti-cancer drugs has proved to be a major barrier in the clinical management of
neoplastic disease. We have investigated the mechanistic basis for resistance to folate-based thymidylate
synthase (TS) inhibitors using two cell lines selected for resistance to ZD1694 (N-(5-jN-(3,4-dihydro-2-methyl-
4oxoquinaolin6-ylmethyl)-V-methylaminoF2-thenoyl)-L-glutamic acid), a drug currently in phase III clinical
trial. The degree of resistance was >20 000 for the human lymphoblastoid cell line W1L2:R and approx-
imately 14 for the ovarian carcinoma cell line CHI:R. In both cases resistance was associated with increased
TS activity. The W1L2:R cell line had an approximately 100-fold increase in TS gene copy number and
mRNA levels and a 500- to 1000-fold increase in enzyme levels determined using quantitative reverse
transcription-polymerase chain reaction (RT-PCR) and Southern and Western blotting. The CHI:R cell line
had an approximately 2- to 2.5-fold increase in TS gene copy number. mRNA and protein levels. In both cell
lines the fold resistance determined was significantly higher than the fold increase in target enzyme DNA.
mRNA or protein levels. Small changes in TS levels may therefore translate to clinically significant alterations
in drug sensitivity.
Keywords: thymidylate synthase (TS); folate-based TS inhibitors; ZD1694. drug resistance: gene
amplification
Resistance to chemotherapeutic agents has proved to be a
major barrier in the clinical management of neoplastic
disease. Where an initial response is seen, continued treat-
ment frequently results in the regrowth of tumour cells resis-
tant to that form of therapy and is often associated with a
decreased response rate to other treatments. Because of the
difficulties involved in the direct study of mechanisms in
clinical samples, the generation ofdrug-resistant cell lines has
been used extensively in the study of innate and acquired
drug resistance. We have adopted this approach to inves-
tigate mechanisms of resistance to folate-based thymidylate
synthase (TS) inhibitors.
TS (EC 2.1.1.45) catalyses the de novo synthesis of dTMP
by the transfer of a one carbon unit from 5,10-CH2-FH4 to
the 5-position of dUMP. The importance of TS activity for
DNA synthesis has made this enzyme an attractive target for
the design of chemotherapeutic agents. Inhibition of TS by
the metabolite FdUMP is considered an important site of
action of the chemotherapeutic agent 5-fluorouracil (5-FU).
Resistance to 5-FU has been associated with elevated levels
of TS in cultured cell lines (Priest and Ledford, 1980; Berger
et al., 1985; Jenh et al., 1985) and in combination with
leucovorin in a human colorectal tumour (Clark et al., 1987).
The importance of TS inhibition to the overall anti-tumour
activity of the fluoropyrimidines has been difficult to estab-
lish, however, owing to the incorporation ofother fluorinated
drug metabolites into RNA (Wilkinson et al., 1975; Kufe and
Major, 1981; Glazer and Lloyd, 1982; Herrick and Kufe,
1984) and DNA (Kufe et al., 1981; Saywer et al., 1984) which
has been associated with cytotoxicity. More recently, folate
analogues have been synthesised which act by forming a
tightly bound non-productive complex with TS and the
natural substrate dUMP. l0-Propargyl-5,8-dideazafolate
(CB3717) was the first folate analogue, designed as an
inhibitor of TS (Jones et al., 1981), to be clinically evaluated
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(Calvert et al.. 1986). Substantial activity against several
tumour types was demonstrated (Calvert et al.. 1986; Bassen-
dine et al., 1987; Sessa et al., 1988), but excessive renal
toxicity owing to poor solubility at low pH resulted in the
withdrawal of this compound from further clinical studies.
ZD1694 has since been chosen as a non-nephrotoxic, highly
active successor to CB3717 (Jackman et al., 1991; Jodrell et
al., 1991). ZD1694 is principally active through its poly-
glutamate forms (Jackman et al., 1991) and is currently being
clinically evaluated in phase III trials.
In this study, the human lymphoblastoid cell line W1L2
and the human ovarian carcinoma cell line CHI have been
selected for resistance to ZD1694. Using Southern, reverse
transcription-polymerase chain reaction and Western techni-
ques we have determined the role of TS expression in deter-
mining resistance in these lines. Establishment details and
biochemical studies of resistance are described in an accom-
panying study (Jackman et al., 1995).
Materals and methods
RPMI-1640 [containing 20 mM 4-(2-hydroxyethyl)-l-pipera-
zine-ethanesulphonic acid buffer and lacking sodium bicar-
bonate and L-glutamine] was from Flow Laboratories (Irvine,
UK). Fetal calf serum was from Imperial Laboratonres (Salis-
bury, UK). Folinic acid (calcium leucovorin 3 mg ml-') was
from David Bull laboratories (Warwick, UK). (±)-L-Tetra-
hydrofolic acid (HCI) (97% pure) was from Fluka (New-
Ulm, Germany). [5-3H]dUMP, [3'2P-dATP (-30 TBq
mmol-') and '"I-labelled protein A fragments (> 1.1 GBq
mg-') were supplied by the Radiochemical Centre (Amer-
sham, Buckinghamshire, UK). [6-3HJdUMP was from Mora-
vek Biochemicals (Brea, CA, USA). Taq polymerase was
purchased from Perkin Elmer Cetus (Norwalk, CT, USA).
Moloney murine leukaemia virus (M-MLV) reverse transcrip-
tase and placental ribonuclease inhibitor were from Gibco
BRL (Gaithersburg, MD, USA). ZD1694 was synthesised
and supplied by ICI Pharmaceuticals PLC (Macclesfield,
Cheshire, UK). All other reagents were purchased from
Fisons (Loughborough, UK), Sigma (London, UK) or
British Drug Houses (BDH) (UK).I Z Dresbn assoiandwiU 1 . ae
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Development ofresistant cell lines
The WIL2:R and CHI:R cell lines were selected by stepwise
increases of ZD1694. The selection, culture and pharmaco-
logical characterisation of these cell lines are described in an
accompanying paper (Jackman et al., submitted for publica-
tion). Resistant cells subcultured in ZD1694-containing
medium were grown in the absence of ZD1694 for 21 days
before all experiments. For the DNA, mRNA and protein
determinations, cells were harvested during logarithmic
growth and either used immediately or frozen as pellets at
- 70°C for future use.
Quantitative Western blotting
Cell samples were washed twice in phosphate-buffered saline
and resuspended at 106 cells per 100yil of sample buffer
(50 mM Tris-Cl pH 6.8, 100 mM dithiothreitol, 1% SDS,
0.2% bromophenol blue and 10% glycerol). Samples were
sonicated briefly to shear the DNA, spun for 5 min in a
microfuge and the supernatants retained. The crude cell
homogenates (10 tLI of each) were separated on 12% SDS-
polyacrylamide gels and transferred to a nitrocellulose mem-
brane (Burnette, 1981). The membranes were blocked in
Tris-buffered saline (TBS) with 0.05% Tween-20 and 5%
fat-free milk powder overnight at 4°C. Subsequent hybridisa-
tion steps were also carried out in the TBS/Tween/milk
powder mixture. The next day the membranes were incubat-
ed with a 1:500 dilution of rabbit polyclonal anti-TS anti-
serum (Freemantle et al., 1991) (kindly provided by Dr
Wynne Aherne, Institute of Cancer Research, Sutton, UK).
After washing, the filters were incubated in a 1:1000 dilution
of '"I-labelled protein A for 1 h at room temperature. After
a final wash to remove excess radiolabel, the membranes
were exposed to X-ray film at -70°C with intensifying
screens. Bands corresponding to TS were analysed using the
PhosphorImaging system to obtain accurate quantification
measurements of the relative levels of radioactivity per band.
cDNA synthesis and quantitative PCR
The PCR assay is based on the method described by
Horikoshi et al. (1992). Total RNA was isolated using the
RNAzol method (Cinna/Biotecx Laboratories International,
Frienswood, TX, USA; Chomczynski and Sacchi, 1987).
cDNA was synthesised from 5 Lg of total RNA with 6tig of
random hexamers in a total volume of 100IA. The reaction
mixture consisted of 50 mM Tris-HCI (pH 8.3), 75 mM
potassium choloride, 3 mM magnesium chloride, 10 mM
dithiothreitol, 1 mM each nucleotide and 600 units of M-
MLV reverse transcriptase. The reaction was incubated at
37°C for 1 h.
For the PCR assay the cDNA samples were diluted in
sterile water depending on transcript abundance. Three
cDNA concentrations for each primer pair were used. For
accurate quantification using this method measurements have
to be taken in the linear phase of the reaction, where cDNA
concentration is directly proportional to signal intensity;
using different cDNA concentrations determines whether this
region of the reaction curve is covered. PCR amplifications
were carried out in a final volume of 25 Id, containing the
target cDNA, 12.5 pM of each primer, 2.5liCi of[Ix-32PdATP
(-30TBqm-') and 2 units of Taq polymerase in 50mM
Tris-HCI (pH 8.3), 75 mm potassium chloride, I mM magne-
sium chloride and 200JLM each of dCT'P, dGTP and dTTP
and 100gM dATP. Each PCR cycle consisted of 1 min of
denaturation at 94°C, 1 min of primer annealing at 55C and
I min of primer extension at 72°C. A total of 25 cycles were
carried out in a Perkin-Elmer/Cetus DNA thermal cycler.
Results are expressed as target mRNA levels relative to the
internal reference standards: 1-actin mRNA and 18S rRNA.
The sequences of the thymidylate synthase (Takeishi et al.,
1985) and P-actin (Ng et al., 1985) primers were the same as
those used by Horikoshi et al. (1991): TS-5'(5'-AGA TCC -
AAC ACA TCC TCC GCT-3'), TS-3' (5'-CCA GAA CAC
ACG TrTT GGT TCTCAG-3'), P-actin-5' (5'-GCG GGA -
AAT CGT GCG TGA CAT T-3') and P-actin-3' (5'-
GAT GGA GTT GAA GGT AGT TTC GTG-3'). The
dihydrofolate reductase (DHFR) mRNA (Chen et al., 1984)
and 18S rRNA (Torczynski et al., 1985) primers were
selected using the primer selection programme designed by
Lowe et al. (1990): DHFR-5' (5'-CCA CAA CCT-
CTT CAG TAG AAG-3'), DHFR-3' (5'-CTT ATT GCC-
TTT CTC CTC CTG G-3'), 18S-5' (5'-GAT GGA GTT
GAA GGT AGT TTC GTG-3') and 18S-3' (5'-GAA CTA
CGA CGG TAT CTG ATC G-3'). All primers were synthe-
sised on an Applied Biosystems 392 DNA/RNA synthesiser.
PCR products were separated on 12% polyacrylamide gels.
To 10gl of each PCR reaction, 3 gl of 5 x sample loading
buffer was added (10% Ficoll, 0.05% bromophenol blue,
0.25% orange G and 0.5% SDS in water). The acrylamide
gels were dried down and radioactive PCR product bands
were located by autoradiography for excision and subsequent
quantification by liquid scintillation counting. Background
control bands from each lane were also excised, and these
counts were subtracted from the PCR product band counts.
Transcript abundance was calculated by relating target
mRNA levels, TS and DHFR, to the internal reference stan-
dard levels, P-actin mRNA and 18S RNA.
DNA analysis
DNA extractions were carried out either using the Applied
Biosystems 340A nucleic acid extractor (Applied Biosystems,
CA, USA) or manually. The initial stages for each method
are identical. Cell membranes were disrupted by gently mix-
ing the cells with nuclear isolation buffer [NIB: 0.25% of
Nonidet P40 (non-ionic detergent), 100 mM sodium chloride,
10 mM Tris-HCI, 1 mM EDTA]. Approximately 2 ml of NIB
was used per 108 cells. The nuclei were then spun down for
5 min at 2000 g (4°C) and the supernatant removed. The
nuclear pellets were resuspended in the same volume of NIB
as before plus a further volume of 2 x lysis buffer (Applied
Biosystems product: urea, sodium chloride, n-lauroyl sar-
cosine and 1,2-cyclohexaminediamine tetra-acetic acid in
Tnrs-HCI, pH 7.9) and proteinase K added to a final concen-
tration of 600gLg ml-'. This mixture was incubated at 60C
for 2 h or until the majority of the protein was digested. For
the automated process the proteinase K digest is loaded onto
the machine which carries out automated phenol-chloroform
extractions and isopropanol precipitations. The final DNA
precipitate is collected onto a filter from which it can be
redissolved in the required solution. For the manual DNA
procedure organic extractions were carried out essentially as
described by Sambrook et al. (1989).
For Southern transfer, DNA samples were digested with
the restriction endonuclease EcoRP, and the fragments
separated by electrophoresis on 0.8% agarose gels before
transfer to and immobilisation on nylon membranes. Probe
hybridisation was carried out under standard conditions at
65'C with a final wash stringency of 2 x standard saline
citrate (1 x = 0.15 M sodium chloride, 0.015M sodium cit-
rate, pH 7.0) and 0.2% sodium dodecyl sulphate (SDS). The
probe used for TS DNA and mRNA analysis was a 0.7 kb
gel-purified fragment of mouse TS cDNA cleaved from the
pMTS-3 plasmid with HindIIl and PstI (Geyer and Johnson,
1984) which was 32P labelled by random primer extension
(Feinberg and Vogelstein, 1983). Equal loading of DNA was
determined by ethidium bromide staining of the gels before
transfer. A non-amplified cross-reacting sequence was evident
in all the samples probed with the TS cDNA probe, and this
was also used to check for equal DNA loading. This
sequence has been previously reported (Berger et al., 1985;
Clark et al., 1987) with the suggestion that this sequence is a
TS pseudogene which exists at an alternative chromosomal
location (Clark et al., 1987). To estimate the degree of TS
gene amplifcation, dilutions of the resistant cell line DNA
and RNA samples were made to obtain a signal of equal
intensity to that produced by undiluted parental DNA. The
membranes were exposed to X-ray film at - 70°C with inten-
sifying screens and for quantification of signals the filterswere analysed using the Phosphorlmager system (Molecular
Dynamics, Sunnyvale, CA, USA).
Reits
For detailed cell characterisation see the accompanying paper
by Jackman et al. in this issue. Briefly, the W1L2:R cell line
was >20000-fold resistant and the CHI:R cell line was
approximately 14-fold resistant to ZD1694. There was an
increase in TS activity in both cell lines (WlL2:R, 514-fold;
and CHI:R, 4.2-fold). There were no significnt differences
in DHFR activity.
Protein analysis
The Western blots in Figure 1 demonstrate the different
levels of TS protein in the resistant vs parental cell lines.
Using the Phosphorlmager the relative amount of 'I-label-
led protein A was quantified in the bands corresponding to
the molecular weight of the human TS monomer (36 kDa).
The results from this analysis and from two repeat experi-
ments show that the total TS protein level in CHI:R cells
was approximately 2.5-fold higher than that of the parental
cell line. TS protein determinations using the W1L2 and
WIL2:R cell lines (Figure lb) indicated that the level of TS
monomer in the resistant cells was elevated by approximately
1000-, 600- and 500-fold from three separate experiments.
DNA analysis
Figure 2 shows the Southern analysis for TS with DNA from
the W1L2 and WIL2:R cell lines. The Phosphorlmager was
used to quantify the relative amounts ofradioactivity in each
band and the difference in TS gene copy number between the
cell lnes was calculated. The increase in TS gene copy
number in the WIL2:R compared with the W1L2 cell line,
calclated from this blot, was 114-fold with a 95% confi-
dence interval of 66- to 162-fold (P = 0.009). In two repeats
of this analysis (not shown) the increase in TS gene copy
number in the WIL2:R cell ie appeared to be approx-
imately 60- to 100-fold.
Figure 3 shows the Southern analysis for TS gene copy
levels for the CHI and CHI:R cell line. The 4.2-fold eleva-
tion in TS catalytic activity in the CHI:R cell line indicated
that if gene ampiftion were the cause of this overexpres-
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the Phosphorlmager the fold increase in TS gene copy
number in the CH1:R compared with the CHI cell line was
2.6-fold with a 95% confidence interval of 1.8- to 3.3-fold
(P = 0.0031 with five degrees of freedom). Two repeat
experiments of this Southern analysis also indicated an app-
roximately 2-fold increase in TS gene copy number in the
CH1:R compared with the CHI cell line.
RNA analysis
Table I shows the results from PCR-based transcription
assays using WIL2, WIL2:R, CHI, and CHE:R cell line
cDNAs. The TS mRNA levels are clearly elevated in the
W1L2:R line compared with the parental W1L2 cell line, the
average difference between the two varying from 82-fold
relative to P-actin mRNA to 128-fold relative to 18S RNA.
The difference between these two values is explained when
the P-actin mRNA relative to 18S rRNA expression ratios
for the two cell lnes are examined: there is a significant
increase in this ratio in the resistant cell line compared with
the parental line (1.4- to 1.5-fold). This may indicate an
increase in the total mRNA transcription level which is either
essential for, or a consequence of, the drug resistance
phenotype.
The reported increase in the TS catalytic activity of the
CHI:R cell line was 4.2-fold and the observed increase in TS
gene copy number from the previous section was approx-
imately 2-fold. A 1.9-fold increase in TS mRNA relative to
P-actin mRNA was seen in the CHI:R line compared with
the CH1 line, which reached significnce in a paired two-
taied t-test (P= 0.0378). A similar increase was seen when
TS mRNA levels were expressed relative to DHFR mRNA
and 18S rRNA levels, but this did not achieve signif .
There was no significant difference in the P-actin/18S expres-
sion ratios between the CHI and CHL:R cell lines.
Northern analysis using total RNA from these cell lines
(not shown) suggested that there was a small increase
(approximately 2-fold) in TS mRNA levels in the resistant
cell line. The sum of the mean values from the three TS
expression ratios (relative to DHFR, P-actin and 18S) indi-
cates that the increase in TS mRNA level, although small








Fugwe 2 Southern analysis of the TS gene from WIL2 and
WIL2:R DNA (EcoRI digest). Lanes I and 2 contain 10 and
5 ag of WIL2 DNA, rctiv, and lanes 3-8 contain 5, 2.5,
1.25, 0.63, 0.32 and 0.15pg of WIL2:R DNA respectively.
-TS monomer
Dilution factor
Fue I Western analysis ofTS in (a) CHI and CHI:R and (b)
W1L2 and WIL2:R total celular protein. The gels were blotted
and the membranes probed with the TS poconal antiserum. TS
monomer molecular weight is -36kDa- (a) Lane I contains 5 ng
of human recombinant TS, lanes 2-4 contain CHI protein and
lanes 5-9 contain CHI:R protein. (b) Lane I contain 5ng of
human recombinant TS, lanes 2-4 contain WIL2 protein and








Fugw 3 Southern analysis of the TS gene from CHI and
CHI:R DNA (EcoRI digest). Lanes 1 and 2 contain 20 and 10 ag
of CHI DNA, respectively, and lanes 3-6 contain 20, 10, 5 and
2j5ag of CHI:R DNA respectively.
A c eTZDiS4 msestm- assodad wlbTShgm -=99EkdNG~
SJ Freernante et a
Table I Results from quantitative PCR-based transcription assays comparing TS, DHFR, P-actin mRNA and 18S rRNA
expression ratios between the parental WIL2 and CHI cell ines and the ZD1694-resistant variants
TS/I-action TS118S DHFRI18S r-actin 18S
Expression ratio (x 10-3) TSIDHFR (x 10-6) DHFRIP-actin (x 10-3) (X l0-3)
W1L2
n 5 2 5 2 2 5
Mean 28 0.47 31 0.055 0.080 1.23
s.d. 11 0.23 6.3 0.023 0.033 0.35
WIL2:R
Mean 2300 48 3900 0.046 0.093 1.73
s.d. 860 31 1850 0.017 0.022 0.48
Mean (fold-change) ± s.e. 89 ± 38 91 ± 20 122 ± 39 0.87 ± 0.07 1.3 ± 0.25 1.5 ± 0.40
P-value paired two-tailed 0.0045 0.0134 0.048
t test
CHI
n 6 3 6 3 3 6
Mean 33 0.33 64 0.13 0.27 2.1
s.d. 17.5 0.067 29 0.031 0.020 0.78
CH1:R
Mean 53 0.53 132 0.131 0.20 2.9
s.d. 20 0.26 86 0.098 0.12 2.7
Mean (fold-change)±s.d. 1.85 ± 0.79 1.7 ± 0.74 2.7 ± 2.4 0.88 ± 0.47 0.76 ± 0.49 1.2 ± 0.64
P-value, paired two-tailed 0.038 0.22 0.178 0.96 0.54 0.46
t test
Fold-change is defined as (value, /value,,w) for each individual determination. n refers to the number of determinations for
each resistant and parental cell line pair.
Tabe H Results summary of the increases in TS gme oDpy number,
mRNA and protn leves, and fold resista to the sekive agent in the
W1L2R and CHL:R cel lines1 Also shown forcomparison are previously
reported data for the W1L2C1 cell ine (O'Connor et al., 1992)
Approximate fold increase
from parental cell line in WJL2:R CHJ:R WJL2:CJ
TS gene copy number -100 2-2.5 64-%
TS mRNA levels 82-128 2 86-135
TS protein levels 500-1000 2.5 125-150
Resistance to selecting agent >20 000 14 27 000
For both cell lines there was no significant difference in the
DHFR/P-actin or DHFR/18S expression ratios between the
parental cell line and the corresponding resistant variant.
The results from the W1L2:R and CH1:R cell lines are
summarised in Table II. In both of the cell lines studied, the
increase in the level of resistance obtained to the selective
agent exceeds the increases in the TS gene copy number,
mRNA, protein or catalytic activity levels determined. In the
CH1:R cell line the increase in TS gene copy number was
associated with a similar increase in TS mRNA and protein;
in the W1L2:R cell line the increase in TS protein levels and
activity exceeds that of the increase in gene copy and mRNA
levels by at least 4-fold.
Two cell lines selected for the ability to grow in high levels of
the folate-based TS inhibitor, ZD1694, were studied to deter-
mine their mechanisms of resistance. Initial studies revealed
increases m TS catalytic activity in both cell lines, and we
found that this was associated with TS gene amplification
and overexpression and not with an alteration in the enzyme
itself. Neither of the resistant cell lines showed evidence of
gene rearrangement involving the EcoRI fragment detected
by Southern blot analysis. This, together with the propor-
tionate increase in TS mRNA levels and maintenance of the
normal transcript sizes in the cell lines, strongly suggested
that the amplified TS genes were intact and transcriptionally
active. The regions of DNA which contain amplified genes
(amplicons) for other genetic markers are reported to range
in size from approximately 50 kb to >10 Mb, which could
comfortably contain the full 16 kb of the biologically active
TS sequence (Kaneda et al., 1990).
The most common biochemical alterations associated with
acquired resistance to the antifolate methotrexate (MTX) are
overexpression of the target enzyme DHFR (Biedler and
Spengler, 1975, 1976; Kaufman, 1979; Flintoff et al., 1982),
altered drug transport (Schuetz et al., 1988; Norris et al.,
1991; Trippett et al., 1992) and altered drug polyglutamation
(McCloskey et al., 1991; Van der Laan et al., 1991). This
pattern would appear to apply equally to the folate-based TS
inhibitor, 21694; cell lines selected for resistance to ZD1694
have also demonstrated these three manifestations of resis-
tance (accompanying study; Jackman et al., 1995).
There were no significant differences in DHFR enzyme
activity or transcript levels between the parental cells and the
ZD1694-resistant variants. This contrasts with the murine
L1210:C15 cell line, selected for a high level of resistance to
the TS inhibitor CB3717, which has been reported to have
approximately 45-fold increased TS gene copy number and
mRNA levels plus a 30- to 40-fold increase in DHFR gene
copy number with a 7-fold elevation of DHFR mRNA levels
(Imam et al., 1987). As DHFR was not overexpressed in
either cell line selected for resistance to ZD1694, it does not
seem to be a prerequisite for cell lines resistant to high levels
of folate-based TS inhibitors to overexpress the DHFR gene
with the TS gene.
In both of the cell lines described in this study the fold
resistance exceeds the fold increase in TS gene copy number,
mRNA and protein levels. Possible explanations relating to
altered transport or polyglutamination are addressed in an
accompanying study (Jackman et al., 1995). The CHI:R cell
line showed similar elevations of TS gene copy number,
mRNA levels, catalytic activity and protein, whereas in the
WIL2:R cell line the fold increase in enzyme activity and TS
monomer was greater than that of TS gene copy number or
mRNA. This suggests an alteration in the level of translation
of TS specific mRNA in W1L2:R cells which could be due to
changes in the transcribed non-coding regions of the
amplified gene, in a translational regulatory protein or even
associated with the probable extrachromosomal location of
the amplified TS genes in this cell line. It has been noted inZDM 4 m-bm inuedliid Wlb 13gm
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three recent reports that translational mechanisms are
involved in the regulation of T1S expression (Kaneda et al.,
1987; Chu et al., 1991; Keyomarsi et al., 1993).
Differences in the naturally occurring levels of1T3 and any
changes in these levels subsequent to drug administration
may be crifical determinants of clinical response to these
agents. Keyomarsi et al. (1993) have reported that, following
ZD1694 treatment, TS activity, but not mRNA kvels, in-
creases by up to 40-fold in normal and lO4old in tumour-
derived cell lines, suggesting a loss ofTS tanslational regula-
tion in the presence ofZD1694. The importance ofTS kwels
to the cytotoxicity of these compounds in vitro is demon-
strated by the cell lines described in this report. For future
consideration it will be ofinterest to relate innate TS kwls to
the activity of these compounds in vitro, in vivo and in the
clinic.
Amwybi. 5,10CHrFH4, 5,10ncthyiene tetrahydrofolc acid; 5-
FU, 5-hloruracil; CB3717, N'°-propargys5,8dideazafohc acid;
cDNA, compentary DNA; D1694, N-(5-IN-(3,4-dihydro-2-meth*
4-oxoquinazoylin-6-yhnehyl)-N-methy- }aMinoj2-thenoyl)L-gJtamic
acid; dATP, deoxyadeosine triphosphate; DHFR, dihydrofolate
as; dUMP, deoxyuridine monophphatee dTMP, thymidine
MODophosphate EDTA, ehD acid; FdUrd, 5-
fluorodeoxyuridie FdUMP, 5fuorodeoxyuridi monophosphate;
FPGS, foypoyta synthetaw; ICI198583, Ckdesamino-
meth*NM rgyl-5,8-ideazafoc acid; PCR, polymerase chain
lion TS, thymidyle synthase.
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